Can Amgen’s Strategic Partnerships Redefine Access and Growth in the GLP‑1 Market?

23 January 2026

Executive Summary

Amgen is actively exploring strategic collaborations with telehealth platforms and other access-focused partners to expand reach for its GLP‑1 therapies. These initiatives are designed not only to broaden patient access and improve adherence, but also to diversify revenue streams, positioning Amgen to capitalize on the rapidly evolving obesity and metabolic disease market. The approach highlights a shift toward digital-first commercialization strategies that integrate patient care, data-driven insights, and innovative distribution channels.

Strategic Insights

1. Expanding Market Access Through Telehealth
   • Telehealth partnerships can unlock access to underserved or remote populations, increasing therapy adoption
   • Facilitates continuous monitoring and follow-up, improving adherence and long-term outcomes
   • Supports data collection on real-world patient experiences, informing pipeline prioritization and product optimization
2. Revenue Diversification and Channel Innovation
   • Beyond traditional clinic- and pharmacy-based channels, digital platforms allow new revenue streams and flexible delivery models
   • Potential for subscription-based or value-based care models, aligning with payer demands and improving market penetration
   • Enhances resilience against reimbursement or pricing pressures, mitigating reliance on single distribution pathways
3. Competitive and Market Positioning
   • Early adoption of hybrid care and digital access solutions differentiates Amgen in the fast-growing, competitive GLP‑1 segment
   • Telehealth integration signals forward-thinking commercialization, which may attract partnerships with insurers, specialty pharmacies, and care networks
   • Demonstrates Amgen’s ability to leverage technology to improve patient outcomes while scaling commercial reach
4. Long-Term Strategic Implications
   • Expanding patient access digitally may reshape treatment norms in obesity and metabolic disease care
   • Positions Amgen to collect actionable patient data, enhancing future therapy development and market responsiveness
   • Strengthens Amgen’s broader portfolio resilience by combining clinical innovation with modern delivery strategies

Industry Context

The GLP‑1 therapy market is rapidly evolving, with patient access, digital engagement, and adherence emerging as key differentiators. Strategic partnerships that integrate telehealth, digital monitoring, and alternative delivery channels are increasingly becoming a competitive necessity rather than a luxury. Amgen’s move aligns with global trends toward hybrid care models and patient-centric commercialization.

Outlook

Amgen’s exploration of telehealth partnerships underscores a strategic commitment to both growth and innovation, combining market access, revenue diversification, and patient-centric care in a single initiative.

Strategic Question:
Can Amgen’s digital-first partnerships transform GLP‑1 therapy access, improve adherence, and create a scalable, data-driven revenue model for long-term market leadership?